Dark

HCM
HUTCHMED (China) Limited
stock NASDAQ ADR

At Close

Jun 16, 2026 3:59:50 PM EDT

10.51USD-2.955%(-0.32)37,184

10.33Bid 10.52Ask 0.19Spread

Pre-market

Jun 15, 2026 8:37:30 AM EDT

11.15USD+2.955%(+0.32)0

After-hours

Jun 16, 2026 4:00:30 PM EDT

10.49USD-0.190%(-0.02)1,349

OverviewOptionsHistoricalExchangesShortsNews

Jan 19, 2022

07:00PM EST HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (CSF-1R) inhibitor. The first patient received their first dose on January 18, 2022. GlobeNewswire Inc

Jan 18, 2022

07:00PM EST HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at GlobeNewswire Inc

Jan 12, 2022

06:44AM EST Hutchmed Gets BTD In China For HMPL-523 To Treat Primary RTTNews

06:08AM EST HUTCHMED Gets Breakthrough Therapy Designation In China For HMPL-523 For Immune Thrombocytopenia RTTNews

06:00AM EST HUTCHMED Receives Breakthrough Therapy Designation in China for GlobeNewswire Inc

Jan 9, 2022

07:00PM EST HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house byHUTCHMED GlobeNewswire Inc

Dec 20, 2021

12:33PM EST HUTCHMED Late Saturday Announced Its Stock Has Been Included BY FTSE Russell In FTSE Global Equity Index Series In Its Qtr. Review, Effective Dec. 20, 2021 Benzinga

Dec 19, 2021

07:00PM EST HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (GEIS) in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021. GlobeNewswire Inc

Dec 14, 2021

12:00AM EST HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-523 presented at the 63rd American Society for Hematologys (ASH) Annual Meeting and Exposition, held virtually and in person at the Georgia World Congress Center in Atlanta, Georgia. GlobeNewswire Inc

Dec 10, 2021

05:00AM EST HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple disease settings, presented at the European Society for Medical Oncologys (ESMO) Immuno-Oncology Congress 2021, taking place virtually on December 8-11, 2021. GlobeNewswire Inc

Dec 5, 2021

07:00PM EST Recruitment of 687 patients globally completed in fifteen months, ahead ofschedule GlobeNewswire Inc

Dec 3, 2021

12:00AM EST HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Administration (NHSA), on January 1, 2022 the updated National Reimbursement Drug List (NRDL) will continue to include ELUNATE (fruquintinib) and will now include SULANDA (surufatinib). GlobeNewswire Inc

Nov 23, 2021

10:04PM EST HUTCHMED, AstraZeneca Initiate Phase III Trial Of RTTNews

07:00PM EST Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET GlobeNewswire Inc

Nov 19, 2021

09:55AM EST Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations PR Newswire

Nov 11, 2021

08:36AM EST International companies to host live webcasts at Deutsche Bank's Depositary PR Newswire

Nov 7, 2021

07:00PM EST HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the GlobeNewswire Inc

Nov 1, 2021

04:54AM EDT HUTCHMED, AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma Benzinga

12:15AM EDT Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO GlobeNewswire Inc

Sep 28, 2021

08:00PM EDT HUTCHMED Announces Closing of Divestment of Non-Core GlobeNewswire Inc

08:00PM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (SULANDA in China) or fruquintinib (ELUNATE in China) with PD-1 inhibitors were presented at the 24th Chinese Society of Clinical Oncology (CSCO) Annual Meeting which has been taking place on September 25-29, 2021. GlobeNewswire Inc

Sep 22, 2021

11:55AM EDT Goldman Sachs Downgrades HUTCHMED (China) to Neutral, Announces $46 Price Target Benzinga

Sep 20, 2021

08:00PM EDT HUTCHMED Initiates SURTORI-01, a Phase III Trial of GlobeNewswire Inc

Sep 19, 2021

08:00PM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated a Japan registration-enabling bridging study for surufatinib to support the registration of surufatinib in the treatment of patients with advanced neuroendocrine tumors (NETs). The first patient was dosed on September 15, 2021. GlobeNewswire Inc

Sep 13, 2021

02:00AM EDT HUTCHMED Receives Breakthrough Therapy Designation in China for GlobeNewswire Inc

Sep 8, 2021

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

06:58AM EDT HUTCHMED, AstraZeneca Initiate SANOVO Phase III Trial Of ORPATHYS And TAGRISSO Combination For Lung Cancer In China RTTNews

06:30AM EDT HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of GlobeNewswire Inc

Sep 7, 2021

04:30AM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3K inhibitor HMPL-689), savolitinib (ORPATHYS in China) and fruquintinib (ELUNATE in China) will be presented at the upcoming 2021 European Society for Medical Oncology (ESMO) Virtual Congress taking place on September 16-21, 2021. GlobeNewswire Inc

Sep 6, 2021

02:00AM EDT HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong GlobeNewswire Inc

Aug 25, 2021

08:00PM EDT HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in GlobeNewswire Inc

Aug 22, 2021

08:00PM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Hang Seng Indexes Company Limited (Hang Seng), including the Hang Seng Composite Index, in accordance with the latest index series release by Hang Seng, with effect from Monday, September 6, 2021. GlobeNewswire Inc

Aug 9, 2021

06:15AM EDT Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China Benzinga

Aug 8, 2021

09:34PM EDT Epizyme Inc. (EPZM) and Hutchmed (China) Limited said that they have collaborated to research, develop, manufacture and commercialize Tazverik or tazemetostat in Greater China, including mainland China, Hong Kong, Macau and Taiwan. RTTNews

08:59PM EDT Epizyme And HUTCHMED Collaborats To Develop & Commercialize TAZVERIK In Greater China RTTNews

08:00PM EDT Collaboration designed to accelerate global development and investigate TAZVERIK combinations with HUTCHMEDs novel oncology medicines portfolio GlobeNewswire Inc

08:00PM EDT Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK(r) (tazemetostat) in Greater China Business Wire

08:00PM EDT Collaboration designed to accelerate global development and investigate TAZVERIK combinations with HUTCHMEDs novel oncology medicines portfolio GlobeNewswire Inc

08:00PM EDT Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK(r) (tazemetostat) in Greater China Business Wire

Aug 3, 2021

08:26AM EDT Jefferies Initiates Coverage On HUTCHMED (China) with Buy Rating, Announces Price Target of $52 Benzinga

Jul 28, 2021

07:10AM EDT HUTCHMED (China) Reports H1-21 Sales $157.4M, Up From $106.8M YoY Benzinga

07:00AM EDT ELUNATE in-market sales1 rose 186%, reflecting impact of in-house sales force GlobeNewswire Inc

Jul 23, 2021

07:00AM EDT Stabilizing Actions and End of Stabilization Period in connection GlobeNewswire Inc

Jul 16, 2021

06:46AM EDT Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine Tumors Benzinga

Jul 15, 2021

08:00PM EDT EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors GlobeNewswire Inc

Jul 13, 2021

06:50AM EDT Hutchmed Gets $25M In Sales Milestone Payment For Orpathys From AstraZeneca Benzinga

02:02AM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS (savolitinib), HUTCHMEDs oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021. GlobeNewswire Inc

Jul 12, 2021

09:54AM EDT HUTCHMED Announces Full Exercise of the Over-allotment Option of GlobeNewswire Inc

Jul 6, 2021

07:42AM EDT HUTCHMED Late Yesterday Announced Co. Initiated Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China Benzinga

Jul 5, 2021

07:00PM EDT HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 GlobeNewswire Inc

Jul 2, 2021

04:30AM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:00 noon British Summer Time (BST) (7:00 pm Hong Kong Time (HKT); 7:00 am Eastern Daylight Time (EDT)). GlobeNewswire Inc

Jul 1, 2021

06:10AM EDT FDA Accepts Filing Of HUTCHMED's Surufatinib NDA For Pancreatic And Extra-pancreatic Neuroendocrine Tumors RTTNews

06:00AM EDT U.S. FDA Accepts Filing of HUTCHMEDs NDA for GlobeNewswire Inc

Jun 30, 2021

05:00AM EDT HUTCHMED Announces the Closing of the Global Offering and the GlobeNewswire Inc

Jun 23, 2021

10:23AM EDT HUTCHMED Announces Pricing of Global Offering GlobeNewswire Inc

05:23AM EDT AstraZeneca Announced Orpathys Approved in China for Lung Cancer Benzinga

Jun 22, 2021

01:16PM EDT HUTCHMED announces savolitinib approved in China for patients with GlobeNewswire Inc

Jun 18, 2021

03:25PM EDT Hutchmed Files For Over $600M Hong Kong IPO Benzinga

11:25AM EDT HUTCHMED Announces NMPA Approval of Surufatinib GlobeNewswire Inc

Jun 17, 2021

07:30PM EDT HUTCHMED Launches Hong Kong Initial Public Offering GlobeNewswire Inc

Jun 6, 2021

08:43PM EDT Innovent Releases Phase 1b Preliminary Results Of TYVYT + Fruquintinib As Treatment For Advanced Colorectal Cancer RTTNews

08:00PM EDT Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021 PR Newswire

May 20, 2021

02:00AM EDT HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and provide a corporate update GlobeNewswire Inc

May 17, 2021

02:00AM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM) today announces that it will host a virtual investor update event on Wednesday, May 26, 2021. Members of the senior management team will provide updates on product launches in China, preparations for US commercialization, R&D, as well as a review of new data presented at the 2021 ASCO Annual Meeting. GlobeNewswire Inc

May 7, 2021

07:00AM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. Eastern Daylight Time (EDT). GlobeNewswire Inc

May 4, 2021

03:00AM EDT Change of Company Name GlobeNewswire Inc

May 3, 2021

07:00AM EDT HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM: HCM) today announces that it completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs). GlobeNewswire Inc

Apr 29, 2021

02:00AM EDT HUTCHMED Initiates Phase II Registration Study of HMPL-689 in GlobeNewswire Inc

Apr 8, 2021

03:30AM EDT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION GlobeNewswire Inc

Mar 29, 2021

02:33AM EDT Hutchison China MediTech Begins Two International Phase I Studies Of HMPL-306 RTTNews

02:00AM EDT HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual GlobeNewswire Inc

Mar 24, 2021

10:29AM EDT Hutchison China Offloads Stake In China OTC Joint Venture For $169M Benzinga

09:36AM EDT HUTCHMED Agrees To Divest Non-Core OTC Joint Venture For $169 Mln RTTNews

09:30AM EDT HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for GlobeNewswire Inc

07:51AM EDT Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study Benzinga

03:36AM EDT HUTCHMED Begins Phase Ib/II Trial Of Surufatinib With Tislelizumab In Advanced Solid Tumors In U.S. And Europe RTTNews

03:00AM EDT HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in GlobeNewswire Inc

Mar 4, 2021

07:00AM EST Hutchison China MediTech Limited GlobeNewswire Inc

Feb 3, 2021

02:00AM EST Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST). GlobeNewswire Inc

Jan 14, 2021

05:00AM EST Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020), taking place on January 28-31, 2021, virtually. GlobeNewswire Inc

Jan 10, 2021

09:00PM EST Hutchison China MediTech Limited (HCM) or Chi-Med and Inmagene Biopharmaceuticals have partnered to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. RTTNews

08:00PM EST Chi-Med and Inmagene Announce Strategic Partnership to Develop and GlobeNewswire Inc

Dec 30, 2020

07:13AM EST Chi-Med Secures NMPA Approval Of Surufatinib For Non-Pancreatic Neuroendocrine Tumors RTTNews

07:00AM EST Sulanda is Chi-Meds first oncology drug brought to market without a partnership and the companys second oncology drug approved inChina GlobeNewswire Inc

Dec 28, 2020

02:17PM EST Hutchison China MediTech Reports Co. Initiated Rolling Submission Of New Drug Application To FDA For Surufatinib For Treatment Of Advanced Neuroendocrine Tumors Benzinga

01:25PM EST Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for GlobeNewswire Inc

Dec 22, 2020

02:00AM EST Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Healthcare Conference taking place virtually on Monday January 11, 2021 at 8a.m. EST (1p.m. GMT / 9p.m. HKT). GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 17, 2020

02:00AM EST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION GlobeNewswire Inc

Nov 5, 2020

04:00AM EST Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be presented as a poster at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place on December 5-8, 2020 virtually. GlobeNewswire Inc

Oct 30, 2020

08:00AM EDT Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences: GlobeNewswire Inc

Sep 20, 2020

08:25AM EDT Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (NET) GlobeNewswire Inc

Sep 17, 2020

06:51AM EDT Chi-Med Announces A Second NDA Acceptance In China For Surufatinib In Pancreatic Neuroendocrine Tumors Benzinga

06:48AM EDT Chi-Med Announces China NMPA Accepts NDA For Surufatinib In Pancreatic Neuroendocrine Tumors RTTNews

06:45AM EDT Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) today announces that its New Drug Application (NDA) for surufatinib for the treatment of patients with advanced pancreatic neuroendocrine tumors (NET) has been accepted for review by the China National Medical Products Administration (NMPA). GlobeNewswire Inc

Sep 4, 2020

02:00AM EDT Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metastatic colorectal cancer (CRC) in the U.S., Europe and Japan. The first patient was dosed on September 3, 2020, in theU.S. GlobeNewswire Inc

Sep 3, 2020

02:04AM EDT Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (FGFR), in patients with advanced intrahepatic cholangiocarcinoma (IHCC), which is a type of liver cancer. GlobeNewswire Inc

Aug 24, 2020

02:00AM EDT Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM)today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place on September 17-21, 2020. GlobeNewswire Inc

Aug 10, 2020

02:33AM EDT Chi-Med Plans To Submit MAA For Surufatinib Following Scientific Advice From EMA's CHMP RTTNews

02:00AM EDT Chi-Med Plans to Submit Marketing Authorization Application for GlobeNewswire Inc

Jul 30, 2020

08:48AM EDT Strong global pipeline progress three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib GlobeNewswire Inc

Jul 28, 2020

02:00AM EDT Chi-Meds NDA for Savolitinib in Non-Small Cell GlobeNewswire Inc

02:00AM EDT Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) and Eli Lilly and Company (Lilly) today announce an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly. The 2020 Amendment covers the expansion of Chi-Meds role in the commercialization of Elunate (fruquintinib capsules) in China. GlobeNewswire Inc

Jul 24, 2020

04:55AM EDT Chi-Med Initiates Phase I Trial Of IDH1/2 Dual Inhibitor In Patients With Hematological Malignancies In China RTTNews

02:00AM EDT HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med GlobeNewswire Inc